These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222 [TBL] [Abstract][Full Text] [Related]
5. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair. Ooki A; Osumi H; Yoshino K; Yamaguchi K Gastric Cancer; 2024 Sep; 27(5):907-931. PubMed ID: 38922524 [TBL] [Abstract][Full Text] [Related]
6. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923 [TBL] [Abstract][Full Text] [Related]
7. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021 [TBL] [Abstract][Full Text] [Related]
8. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576 [TBL] [Abstract][Full Text] [Related]
10. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched. Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431 [TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. González I; Goyal B; Xia MD; Pai RK; Ma C Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Mei WJ; Mi M; Qian J; Xiao N; Yuan Y; Ding PR Front Immunol; 2022; 13():1019582. PubMed ID: 36618386 [TBL] [Abstract][Full Text] [Related]
14. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy. Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995 [TBL] [Abstract][Full Text] [Related]
16. Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs. Inanaga S; Igase M; Sakai Y; Hagimori K; Sunahara H; Horikirizono H; Itamoto K; Baba K; Ohsato Y; Mizuno T J Vet Intern Med; 2022 Sep; 36(5):1760-1769. PubMed ID: 35959511 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P Cells; 2021 Jul; 10(8):. PubMed ID: 34440647 [TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France. Roset M; Amonkar M; Patel R; Lara N; Kothari S Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy. Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098 [TBL] [Abstract][Full Text] [Related]
20. Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action. Fornaro L; Lonardi S; Catanese S; Nappo F; Pietrantonio F; Pellino A; Angerilli V; Signorini F; Salani F; Murgioni S; Neculaescu IA; Bruno R; Vivaldi C; Ricagno G; Masi G; Bergamo F; Ugolini C; Fassan M Gastric Cancer; 2023 Nov; 26(6):958-968. PubMed ID: 37382783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]